level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.droperidolMonitor Closely (2)droperidol and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. droperidol and prochlorperazine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)prochlorperazine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.duloxetineMinor (1)duloxetine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.efavirenzMonitor Closely (1)efavirenz and prochlorperazine both decrease QTc interval. Use Caution/Monitor.eliglustatMonitor Closely (1)eliglustat and prochlorperazine both decrease QTc interval. Use Caution/Monitor.enalaprilMinor (1)prochlorperazine increases effects of enalapril by unspecified interaction mechanism. Minor/Significance Unknown.encorafenibMonitor Closely (1)encorafenib and prochlorperazine both decrease QTc interval. Use Caution/Monitor.entrectinibMonitor Closely (1)entrectinib and prochlorperazine both decrease QTc interval. Use Caution/Monitor.ephedrineMonitor Closely (2)prochlorperazine, ephedrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. prochlorperazine increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.epinephrineMonitor Closely (3)prochlorperazine, epinephrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. prochlorperazine decreases effects of epinephrine by pharmacodynamic antagonism. Use Caution/Monitor. Block pressor response to epinephrine, which may result in severe hypotension and tachycardia. prochlorperazine increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)epinephrine and prochlorperazine both increase QTc interval. Avoid or Use Alternate Drug.epinephrine racemicMonitor Closely (2)prochlorperazine decreases effects of epinephrine racemic by pharmacodynamic antagonism. Use Caution/Monitor. Block pressor response to epinephrine, which may result in severe hypotension and tachycardia. prochlorperazine increases and epinephrine racemic decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)epinephrine racemic and prochlorperazine both increase QTc interval. Avoid or Use Alternate Drug.eribulinMonitor Closely (1)eribulin and prochlorperazine both decrease QTc interval. Use Caution/Monitor.erythromycin baseSerious - Use Alternative (1)prochlorperazine and erythromycin base both increase QTc interval. Avoid or Use Alternate Drug.erythromycin ethylsuccinateSerious - Use Alternative (1)prochlorperazine and erythromycin ethylsuccinate both increase QTc interval. Avoid or Use Alternate Drug.erythromycin lactobionateSerious - Use Alternative (1)prochlorperazine and erythromycin lactobionate both increase QTc interval. Avoid or Use Alternate Drug.erythromycin stearateSerious - Use Alternative (1)prochlorperazine and erythromycin stearate both increase QTc interval. Avoid or Use Alternate Drug.estazolamMonitor Closely (1)estazolam and prochlorperazine both increase sedation. Use Caution/Monitor.ethanolMonitor Closely (1)prochlorperazine and ethanol both increase sedation. Use Caution/Monitor.Minor (1)ethanol, prochlorperazine. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive CNS depression.etomidateMonitor Closely (1)etomidate and prochlorperazine both increase sedation. Use Caution/Monitor.eucalyptusMinor (1)prochlorperazine and eucalyptus both increase sedation. Minor/Significance Unknown.fenfluramineMonitor Closely (2)prochlorperazine, fenfluramine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. prochlorperazine increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.fentanylSerious - Use Alternative (1)fentanyl, prochlorperazine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.fentanyl intranasalSerious - Use Alternative (1)fentanyl intranasal, prochlorperazine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.fentanyl transdermalSerious - Use Alternative (1)fentanyl transdermal, prochlorperazine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.fentanyl transmucosalSerious - Use Alternative (1)fentanyl transmucosal, prochlorperazine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.fesoterodineMonitor Closely (3)fesoterodine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. fesoterodine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. prochlorperazine increases effects of fesoterodine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.fingolimodMonitor Closely (1)fingolimod and prochlorperazine both decrease QTc interval. Use Caution/Monitor.flavoxateMonitor Closely (3)flavoxate decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. flavoxate decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. prochlorperazine increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.flecainideMonitor Closely (1)prochlorperazine and flecainide both increase QTc interval. Modify Therapy/Monitor Closely.fluconazoleSerious - Use Alternative (1)prochlorperazine and fluconazole both increase QTc interval. Avoid or Use Alternate Drug.fluoxetineMonitor Closely (2)prochlorperazine and fluoxetine both increase QTc interval. Use Caution/Monitor. fluoxetine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.fluphenazineMonitor Closely (2)fluphenazine and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. fluphenazine and prochlorperazine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)fluphenazine and prochlorperazine both increase QTc interval. Avoid or Use Alternate Drug.flurazepamMonitor Closely (1)flurazepam and prochlorperazine both increase sedation. Use Caution/Monitor.fluvoxamineMonitor Closely (1)fluvoxamine and prochlorperazine both increase QTc interval. Use Caution/Monitor.formoterolMonitor Closely (1)prochlorperazine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)prochlorperazine and formoterol both increase QTc interval. Avoid or Use Alternate Drug.foscarnetMonitor Closely (1)prochlorperazine and foscarnet both increase QTc interval. Modify Therapy/Monitor Closely.fosinoprilMinor (1)prochlorperazine increases effects of fosinopril by unspecified interaction mechanism. Minor/Significance Unknown.ganaxoloneMonitor Closely (1)prochlorperazine and ganaxolone both increase sedation. Use Caution/Monitor.gemifloxacinMonitor Closely (1)gemifloxacin and prochlorperazine both decrease QTc interval. Use Caution/Monitor.gilteritinibMonitor Closely (1)gilteritinib and prochlorperazine both decrease QTc interval. Use Caution/Monitor.glycopyrrolateMonitor Closely (1)prochlorperazine increases effects of glycopyrrolate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.Minor (1)prochlorperazine increases toxicity of glycopyrrolate by unknown mechanism. Minor/Significance Unknown.glycopyrrolate inhaledMonitor Closely (3)glycopyrrolate inhaled decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. glycopyrrolate inhaled decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. prochlorperazine increases effects of glycopyrrolate inhaled by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.Minor (1)prochlorperazine increases toxicity of glycopyrrolate inhaled by unknown mechanism. Minor/Significance Unknown.glycopyrronium tosylate topicalMonitor Closely (1)glycopyrronium tosylate topical, prochlorperazine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of glycopyrronium tosylate topical with other anticholinergic medications may result in additive anticholinergic adverse effects.granisetronMonitor Closely (1)granisetron and prochlorperazine both decrease QTc interval. Use Caution/Monitor.guanfacineMonitor Closely (1)guanfacine, prochlorperazine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium.haloperidolMonitor Closely (2)haloperidol and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. haloperidol and prochlorperazine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)prochlorperazine and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.Minor (1)haloperidol will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.henbaneMonitor Closely (3)henbane decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. henbane decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. prochlorperazine increases effects of henbane by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.homatropineMonitor Closely (3)homatropine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. homatropine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. prochlorperazine increases effects of homatropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.hydrocodoneSerious - Use Alternative (1)hydrocodone, prochlorperazine. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation. Increased risk of hypotension if ability to maintain blood pressure has been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (eg, phenothiazines or general anesthetics).hydromorphoneMonitor Closely (1)hydromorphone and prochlorperazine both increase sedation. Use Caution/Monitor.hydroxyzineMonitor Closely (2)hydroxyzine and prochlorperazine both decrease QTc interval. Use Caution/Monitor. hydroxyzine and prochlorperazine both increase sedation. Use Caution/Monitor.hyoscyamineMonitor Closely (3)hyoscyamine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. hyoscyamine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. prochlorperazine increases effects of hyoscyamine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.hyoscyamine sprayMonitor Closely (3)prochlorperazine increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. hyoscyamine spray decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. hyoscyamine spray decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.ibutilideContraindicated (1)prochlorperazine and ibutilide both increase QTc interval. Contraindicated.iloperidoneMonitor Closely (3)prochlorperazine and iloperidone both increase QTc interval. Modify Therapy/Monitor Closely. iloperidone and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. iloperidone and prochlorperazine both increase sedation. Use Caution/Monitor.imatinibMinor (1)imatinib will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.imidaprilMinor (1)prochlorperazine increases effects of imidapril by unspecified interaction mechanism. Minor/Significance Unknown.imipramineMonitor Closely (2)prochlorperazine and imipramine both increase QTc interval. Use Caution/Monitor. prochlorperazine and imipramine both increase sedation. Use Caution/Monitor.Minor (2)imipramine, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects. imipramine, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.incobotulinumtoxinAMonitor Closely (1)prochlorperazine, incobotulinumtoxinA. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects.indapamideContraindicated (1)prochlorperazine and indapamide both increase QTc interval. Contraindicated.insulin degludecMonitor Closely (1)prochlorperazine decreases effects of insulin degludec by Other (see comment). Use Caution/Monitor. Comment: Phenothiazines may increase blood glucose concentrations.insulin degludec/insulin aspartMonitor Closely (1)prochlorperazine decreases effects of insulin degludec/insulin aspart by Other (see comment). Use Caution/Monitor. Comment: Phenothiazines may increase blood glucose concentrations.insulin inhaledMonitor Closely (1)prochlorperazine decreases effects of insulin inhaled by Other (see comment). Use Caution/Monitor. Comment: Phenothiazines may increase blood glucose concentrations.ipratropiumMonitor Closely (3)ipratropium decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. ipratropium decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. prochlorperazine increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.isofluraneMonitor Closely (1)isoflurane and prochlorperazine both decrease QTc interval. Use Caution/Monitor.isoproterenolMonitor Closely (2)prochlorperazine, isoproterenol. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. prochlorperazine increases and isoproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.itraconazoleSerious - Use Alternative (1)prochlorperazine and itraconazole both increase QTc interval. Avoid or Use Alternate Drug.ketamineMonitor Closely (1)ketamine and prochlorperazine both increase sedation. Use Caution/Monitor.ketoconazoleSerious - Use Alternative (1)prochlorperazine and ketoconazole both increase QTc interval. Avoid or Use Alternate Drug.ketotifen, ophthalmicMonitor Closely (1)prochlorperazine and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.lapatinibMonitor Closely (1)prochlorperazine and lapatinib both increase QTc interval. Modify Therapy/Monitor Closely.lasmiditanMonitor Closely (1)lasmiditan, prochlorperazine. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.lemborexantMonitor Closely (1)lemborexant, prochlorperazine. Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects.levalbuterolMonitor Closely (1)prochlorperazine increases and levalbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.levodopaSerious - Use Alternative (1)prochlorperazine decreases effects of levodopa by pharmacodynamic antagonism. Avoid or Use Alternate Drug.levodopa inhaledSerious - Use Alternative (1)prochlorperazine decreases effects of levodopa inhaled by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Phenothiazine/1st generation antipsychotics inhibit dopamine D2 receptors